MX2009009060A - Un metodo de identificacion de celulas que muestren sensibilidad a la modulacion de la señalizacion mediada por un receptor del factor de crecimiento de fibroplastos o una variante del mismo. - Google Patents

Un metodo de identificacion de celulas que muestren sensibilidad a la modulacion de la señalizacion mediada por un receptor del factor de crecimiento de fibroplastos o una variante del mismo.

Info

Publication number
MX2009009060A
MX2009009060A MX2009009060A MX2009009060A MX2009009060A MX 2009009060 A MX2009009060 A MX 2009009060A MX 2009009060 A MX2009009060 A MX 2009009060A MX 2009009060 A MX2009009060 A MX 2009009060A MX 2009009060 A MX2009009060 A MX 2009009060A
Authority
MX
Mexico
Prior art keywords
cells
growth factor
fibroblast growth
variant
modulation
Prior art date
Application number
MX2009009060A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Vito Guagnano
Diana Graus Porta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009009060A publication Critical patent/MX2009009060A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se basa en el descubrimiento de que las células que muestran fosforilación (especialmente de tirosina) del sustrato del FGF-lR 2 (FRS-2), en contraste con las células que carecen de esta fosforilación, permiten hacer una predicción de que el tratamiento con un modulador, en especial con un inhibidor, de la señalización del receptor del factor de crecimiento de fibroblastos, tendrá éxito en las células, por ejemplo, a partir de muestras biológicas de pacientes que muestren esta fosforilación. Por consiguiente, la fosforilación del FRS-2 puede servir como un biomarcador de la posibilidad del tratamiento de éxito. La invención se refiere a diferentes métodos, usos, kits, y reactivos útiles en la aplicación de este biomarcador.
MX2009009060A 2007-02-27 2008-02-25 Un metodo de identificacion de celulas que muestren sensibilidad a la modulacion de la señalizacion mediada por un receptor del factor de crecimiento de fibroplastos o una variante del mismo. MX2009009060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103094 2007-02-27
PCT/EP2008/052271 WO2008104523A1 (en) 2007-02-27 2008-02-25 A method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof

Publications (1)

Publication Number Publication Date
MX2009009060A true MX2009009060A (es) 2009-08-31

Family

ID=38134144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009060A MX2009009060A (es) 2007-02-27 2008-02-25 Un metodo de identificacion de celulas que muestren sensibilidad a la modulacion de la señalizacion mediada por un receptor del factor de crecimiento de fibroplastos o una variante del mismo.

Country Status (16)

Country Link
US (2) US20100075337A1 (es)
EP (1) EP2132574A1 (es)
JP (1) JP2010518869A (es)
KR (1) KR20090123870A (es)
CN (1) CN101632021A (es)
AU (1) AU2008220821B2 (es)
BR (1) BRPI0807696A2 (es)
CA (1) CA2677986A1 (es)
IL (1) IL200167A0 (es)
MA (1) MA31203B1 (es)
MX (1) MX2009009060A (es)
NZ (1) NZ578716A (es)
RU (1) RU2519223C2 (es)
TN (1) TN2009000348A1 (es)
WO (1) WO2008104523A1 (es)
ZA (1) ZA200905226B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3256473A4 (en) * 2015-02-12 2018-08-01 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
AU2016262631A1 (en) * 2015-05-14 2017-11-30 Expression Pathology, Inc. SRM/MRM assay for the fibroblast growth factor receptor 2 (FGFR2) protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310181B1 (en) * 1996-12-03 2001-10-30 New York University Medical Center Adaptor protein FRS2 and related products and methods
WO2005115363A2 (en) * 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction

Also Published As

Publication number Publication date
MA31203B1 (fr) 2010-02-01
WO2008104523A1 (en) 2008-09-04
IL200167A0 (en) 2010-04-15
TN2009000348A1 (en) 2010-12-31
RU2519223C2 (ru) 2014-06-10
US20100075337A1 (en) 2010-03-25
BRPI0807696A2 (pt) 2014-05-27
CA2677986A1 (en) 2008-09-04
ZA200905226B (en) 2010-04-28
AU2008220821A1 (en) 2008-09-04
EP2132574A1 (en) 2009-12-16
JP2010518869A (ja) 2010-06-03
US20120315648A1 (en) 2012-12-13
AU2008220821B2 (en) 2012-09-13
KR20090123870A (ko) 2009-12-02
NZ578716A (en) 2012-02-24
CN101632021A (zh) 2010-01-20
RU2009135864A (ru) 2011-04-10

Similar Documents

Publication Publication Date Title
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
EP2315034A3 (en) Means and methods for assessing the risk of cardiac interventions based on GDF-15
WO2005071110A3 (en) Improving polynucleotide ligation reactions
ATE525482T1 (de) Nanoreporter und verfahren zu deren herstellung und verwendung
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
PT2082226E (pt) Análise sequencial de amostras biológicas
WO2007100506A3 (en) Mass tags for quantitative analyses
EP4357783A3 (en) Highly sensitive system and methods for analysis of troponin
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
EP2987866A3 (en) Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
DE602006021223D1 (de) Verfahren zur identifizierung von trpv2-modulatoren
WO2010019414A3 (en) Detecting nucleic acid
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
ATE546543T1 (de) Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
TN2009000348A1 (en) A method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof
MX2009008525A (es) La determinacion cuantitativa de risedronato en orina mediante spe-lc-ms-ms.
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
MX2019012169A (es) Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b).

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration